natalizumab (Q386119)

From Wikidata
Jump to navigation Jump to search
pharmaceutical drug
  • AN100226m
  • PB006
  • anti-alpha4 integrin
  • anti-VLA4
  • antegran
  • natalizumab-sztn
edit
Language Label Description Also known as
English
natalizumab
pharmaceutical drug
  • AN100226m
  • PB006
  • anti-alpha4 integrin
  • anti-VLA4
  • antegran
  • natalizumab-sztn

Statements

subclass of
protein
0 references
side effect
headache
0 references
fatigue
0 references
arthralgia
0 references
gastroenteritis
0 references
vaginitis
0 references
mental depression
0 references
nausea
0 references
legal status (medicine)
boxed warning
1 reference
reference URL
https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802
title
FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

Identifiers

HSDB ID
8174
1 reference
stated in
Hazardous Substances Data Bank
HSDB ID
8174
publication date
28 October 2019
title
Natalizumab (English)
retrieved
10 May 2021
DrugBank ID
DB00108
0 references
DeCS ID
55977
0 references
Microsoft Academic ID
2781004633
0 references
2910384055
0 references
 
edit
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  Retrieved from "https://www.wikidata.org/w/index.php?title=Q386119&oldid=2190040567"